Clinical Trial Update: Treatment of Androgenetic Alopecia in Men for 24 Weeks [Phase 3]

View source ↗

Summary

The document reports completion of a Phase 3 trial evaluating a treatment for androgenetic alopecia in men over 24 weeks.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgenetic Alopecia

Snippet

Sponsor: Eurofarma Laboratorios S.A. | Conditions: Alopecia | Phase 3 | Status: COMPLETED